Trials / Completed
CompletedNCT03478969
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
Patient-Reported Outcomes With the Accu-Chek® Solo Micropump System vs. Multiple Daily Injection Therapy vs. Mylife OmniPod® in Patients With Type 1 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction. In addition, a third arm is included to compare to only similar product on the market which is OmniPod. The third arm is for data collection purpose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Accu-Chek® Solo micropump system | Medical device for subcutaneous delivery of insulin in a personalized way. |
| DEVICE | mylife™ OmniPod® Insulin Management System | A patch pump system delivering insulin. |
| OTHER | Multiple Daily Injections (MDI) therapy | Injecting insulin as per participant's need. |
Timeline
- Start date
- 2018-05-17
- Primary completion
- 2020-05-18
- Completion
- 2020-05-18
- First posted
- 2018-03-27
- Last updated
- 2021-08-20
- Results posted
- 2021-08-16
Locations
21 sites across 4 countries: Austria, Germany, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT03478969. Inclusion in this directory is not an endorsement.